Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Debt (2016 - 2025)

Haemonetics has reported Total Debt over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Total Debt at $1.2 billion for Q4 2025, changed 0.01% from a year ago — trailing twelve months through Dec 2025 was $1.2 billion (changed 0.01% YoY), and the annual figure for FY2025 was $1.2 billion, up 51.62%.
  • Total Debt for Q4 2025 was $1.2 billion at Haemonetics, roughly flat from $1.2 billion in the prior quarter.
  • Over the last five years, Total Debt for HAE hit a ceiling of $1.2 billion in Q3 2024 and a floor of $707.6 million in Q2 2021.
  • Median Total Debt over the past 5 years was $796.1 million (2021), compared with a mean of $936.1 million.
  • Biggest five-year swings in Total Debt: soared 150.89% in 2022 and later dropped 6.79% in 2023.
  • Haemonetics' Total Debt stood at $780.8 million in 2021, then fell by 1.79% to $766.8 million in 2022, then rose by 13.54% to $870.6 million in 2023, then surged by 40.69% to $1.2 billion in 2024, then dropped by 0.01% to $1.2 billion in 2025.
  • The last three reported values for Total Debt were $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.